Impact of serum C-reactive protein measurements in the first 2 days on the 30-day mortality in hospitalized patients with severe community-acquired pneumonia: A cohort study

Journal of Critical Care

Volumn 28, Issue 3, 2013, Pages 291-295

  Nseir, William ^a,b   Farah, Raymond ^b,c   Mograbi, Julnar ^a   Makhoul, Nicola ^b,d  

^a Israel   (Israel)

^b BAR ILAN UNIVERSITY   (Israel)

^c Rebecca Sieff Government Hospital   (Israel)

^d Obstetrics and Gynecology Department   (Israel)

Author keywords

30 day mortality; C reactive protein (CRP); Community acquired pneumonia; Fractional decrease in CRP

Indexed keywords

C REACTIVE PROTEIN;

ADULT; AGED; ARTICLE; CAUSE OF DEATH; COHORT ANALYSIS; COMMUNITY ACQUIRED PNEUMONIA; CONTROLLED STUDY; DISEASE SEVERITY; FEMALE; HOSPITAL PATIENT; HUMAN; LENGTH OF STAY; MAJOR CLINICAL STUDY; MALE; MORTALITY; PROTEIN BLOOD LEVEL; SEX RATIO; SURVIVAL RATE; SURVIVAL TIME; SURVIVOR;

AGED; C-REACTIVE PROTEIN; CHI-SQUARE DISTRIBUTION; COMMUNITY-ACQUIRED INFECTIONS; FEMALE; HOSPITAL MORTALITY; HUMANS; ISRAEL; MALE; MIDDLE AGED; PNEUMONIA; PREDICTIVE VALUE OF TESTS; PROSPECTIVE STUDIES; REGRESSION ANALYSIS; SEVERITY OF ILLNESS INDEX; SURVIVAL RATE;

EID: 84876859285     PISSN: 08839441     EISSN: 15578615     Source Type: Journal    
DOI: 10.1016/j.jcrc.2012.09.012     Document Type: Article

References (27)

1. World Health Organization (WHO). The top 10 causes of death (2008). Fact Sheet No. 310. Updated June 2011. http://www.who.int/mediacentre/factsheets/fs310/en/index.html.
2. Baudouin S.V. The pulmonary physician in critical care.3: critical care management of community acquired pneumonia. Thorax 2002, 57:267-271.
3. British Thoracic Society Standards of Care Committee: BTS Guidelines for the management of community acquired pneumonia in adults. Thorax 2001, 56:IV1-IV64.
4. Hawkey P.M., Jones A.M. The changing epidemiology of resistance. J Antimicrob Chemother 2009, 64(Suppl 1):i3-i10.
5. Christ-Crain M., Opal S.M. Clinical review: the role of biomarkers in the diagnosis and management of community acquired pneumonia. Crit Care 2010, 14:203.
6. Almirall J., Bolíbar I., Toran P., et al. Contribution of C-reactive protein to the diagnosis and assessment of severity of community-acquired pneumonia. Chest 2004, 125:1335-1342.
7. Justo D., Lachmi S., Saar N., et al. C-reactive protein velocity following antibiotics in patients with chronic obstructive pulmonary disease exacerbation and community acquired pneumonia. Eur J Intern Med 2009, 20:518-521.
8. Joffe E., Justo D., Mashav N., et al. C-reactive protein to distinguish pneumonia from acute decompensated heart failure. Clin Biochem 2009, 42:1628-1634.
9. Bafadhel M., Clark T.W., Reid C., et al. Procalcitonin and C-reactive protein in hospitalized adult patients with community-acquired pneumonia or exacerbation of asthma or COPD. Chest 2011, 139:1410-1418.
10. Bruns A.H., Oosterheert J.J., Hak E., et al. Usefulness of consecutive C-reactive protein measurements in follow-up of severe community-acquired pneumonia. Eur Respir J 2008, 32:726-732.
11. Muller B., Harbarth S., Stolz D., et al. Diagnostic and prognostic accuracy of clinical and laboratory parameters in community-acquired pneumonia. BMC Infect Dis 2007, 7:10.
12. Ramirez P., Ferrer M., Marti V., et al. Inflammatory biomarkers and prediction for intensive care unit admission in severe community-acquired pneumonia. Crit Care Med 2011, 39:2211-2217.
13. Lim W.S., van der Eerden M.M., Laing R., et al. Defining community acquired pneumonia severity on presentation to hospital: an international derivation and validation study. Thorax 2003, 58:377-382.
14. Fine M.J., Auble T.E., Yealy D.M., et al. A prediction rule to identify low-risk patients with community-acquired pneumonia. N. Engl. J. Med 1997, 336:243-250.
15. Gracia Vazquez E., Martinez J.A., Mensa J., et al. C-reactive protein levels in community-acquired pneumonia. Eur Respir J. 2003, 21:702-705.
16. Requejo H.I., Cocoza A.M. C-reactive protein in the diagnosis of community-acquired pneumonia. Braz J Infect Dis 2003, 7:C241-C244.
17. Thiem U., Niklaus D., Sehlhoff B., et al. C-reactive protein, severity of pneumonia and mortality in elderly, hospitalized patients with community-acquired pneumonia. Age Ageing 2009, 38:693-697.
18. Menéndez R., Martinez R., Reyes S., et al. Stability in community-acquired pneumonia: one step forward with markers?. Thorax 2009, 64:987-992.
19. Ruiz-González A., Falguera M., Porcel J.M., et al. C-reactive protein discriminating treatment failure from slow responding pneumonia. Eur J Intern Med 2010, 21:548-552.
20. Chalmers J.D., Singanayagam A., Hill A.T. C-reactive protein is an independent predictor of severity in community-acquired pneumonia. Am J Med 2008, 121:219-225.
21. Confalonieri M., Urbino R., Potena A., et al. Hydrocortisone infusion for severe community-acquired pneumonia: a preliminary randomized study. Am J Respir Crit Care Med 2005, 171:242-248.
22. Mikami K., Suzuki M., Kitagawa H., et al. Efficacy of corticosteroids in the treatment of community-acquired pneumonia requiring hospitalization. Lung 2007, 185:249-255.
23. Confalonieri M., Meduri G.U. Glucocorticoid treatment in community-acquired pneumonia. Lancet 2011, 377:1982-1984.
24. Lippi G., Meschi T., Cervellin G. Inflammatory biomarkers for the diagnosis, monitoring and follow-up of community-acquired pneumonia: clinical evidence and perspectives: review article. Eur J Intern Med 2011, 22:460-465.
25. Salluh J.I., Soares M., Coelho L.M., et al. Impact of systemic corticosteroids on the clinical course and outcomes of patients with severe community-acquired pneumonia: a cohort study. J Crit Care 2011, 26:193-200.
26. Perren A., Cerutti B., Lepori M., et al. Influence of steroids on procalcitonin and C-reactive protein in patients with COPD and community-acquired pneumonia. Infection 2008, 36:163-166.
27. Chiang W.C., Teoh O.H., Chong C.Y., et al. Epidemiology, clinical characteristics and antibacterial resistance patterns of community-acquired pneumonia in 1702 hospitalized children in Singapore. Respirology 2007, 12:254-261.